BioCentury
ARTICLE | Financial News

Alpine raises $48M series A round

June 14, 2016 1:14 AM UTC

Alpine Immune Sciences Inc. (Seattle, Wash.) raised $48 million in a series A round led by OrbiMed Advisors. Frazier Healthcare Partners and seed investor Alpine BioVentures also participated.

Alpine is developing multispecific proteins to achieve the effects of immunotherapy combinations, but with more control and using a single molecule. The company's vIgD (variant immunoglobulin domain) platform is based upon endogenous proteins that exist within the synapse between an immune cell and its target cell (see BioCentury, Feb. 8). ...